RecruitingPhase 1NCT07409805

YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment

Evaluation of Safety and Efficacy of YMN-136 Vaccine in Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment: A Prospective Phase I Clinical Study

Sponsor

West China Hospital

Enrollment

9 participants

Start Date

May 6, 2026

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer

Summary

This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with metastatic colorectal cancer.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called YMN-136 Vaccine for people with colorectal, cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALYMN-136 Vaccine

The YMN-136 vaccine will be administered according to the dose level assigned to each patient. Approximately every 3 weeks, the vaccine will be administered via intramuscular injection into the single upper arm, with 4 doses for prime immunization.